Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Irinotecan (CPT-11): Mechanism and Research Use
2026-08-12
Irinotecan, also called CPT-11, is a carboxylesterase-activated topoisomerase I inhibitor used to investigate DNA damage, apoptosis, and colorectal cancer biology. Its research value is supported by cell-line cytotoxicity data, xenograft activity, and mechanistic studies linking treatment-associated liver injury to gut–liver axis dysfunction.
-
CUDC-907: Practical Dual-Pathway Assay Guide
2026-08-12
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of signaling, chromatin-associated responses, cell-cycle progression, and apoptosis. This guide translates the product dossier into an executable workflow and defines boundaries for interpretation; the compound is not intended for diagnostic, therapeutic, or clinical use.
-
Hoechst 33342/PI Double Staining Kit Guide
2026-08-11
The Hoechst 33342/PI Double Staining Kit provides a two-color fluorescent apoptosis assay based on chromatin condensation and membrane integrity. The K2237 workflow supports rapid research differentiation of viable, apoptotic, and necrotic cell populations, but fluorescence patterns require controls and do not establish a complete death mechanism.
-
CARMIL Membrane Binding Controls Actin Assembly
2026-08-11
Mooren and colleagues show that the CARMIL membrane-binding domain is not merely a membrane anchor: it recruits the CPI and CSI motifs to activate capping protein and can subsequently disengage after capping protein binding. This provides a mechanistic model for coupling membrane targeting, barbed-end regulation, and Arp2/3-dependent actin assembly.
-
4-tert-Butylphenol-Induced Ferroptosis in Carp Hepatocytes
2026-08-10
Cui and colleagues show that the environmental pollutant 4-tert-butylphenol damages common carp liver through oxidative stress, iron overload, and disruption of the SLC7A11/GSH/GPX4 and ATF4/HSPA5/GPX4 pathways. By combining animal exposure, primary hepatocytes, toxicogenomics, and Ferrostatin-1 rescue experiments, the study provides mechanistic evidence that ferroptosis contributes to aquatic pollutant hepatotoxicity.
-
Carboxylesterase Artifacts in Mitochondrial H2O2 Assays
2026-08-09
Miwa and colleagues showed that carboxylesterases can convert Amplex Red to resorufin without hydrogen peroxide, horseradish peroxidase, or oxygen, challenging assumptions about mitochondrial H2O2 measurements. The study provides a practical framework for detecting and controlling this interference in oxidative stress assay workflows.
-
Ziprasidone Augmentation in Anxious Depression
2026-08-08
This post-hoc analysis examined whether anxious depression moderated the effects of ziprasidone added to escitalopram after inadequate SSRI response. Depression outcomes were comparable across anxious and nonanxious subgroups, while the apparent anxiety benefit was not clinically meaningful in patients with higher baseline anxiety.
-
LY364947 and the Next Logic of EMT Translation
2026-08-07
LY364947 is more than a pathway inhibitor: it is a mechanistic tool for separating TGF-β-driven signaling from the broader biology of EMT, tumor progression, fibrosis, and retinal injury. This thought-leadership perspective connects selective TGF-β type I receptor kinase inhibition with recent CDK4/6–BET research, offering translational researchers a practical framework for target engagement, assay design, cross-pathway interpretation, and responsible preclinical positioning.
-
Microglial Nr4a1 and Neuronal C3 Drive Synaptic Loss in TMJ
2026-08-07
This study reveals a mechanistic link between peripheral temporomandibular joint (TMJ) inflammation and hippocampal synaptic loss mediated by microglial Nr4a1 deficiency and neuronal C3 deposition. The findings clarify how neuroimmune interactions drive depression-like behaviors, highlighting potential molecular targets for intervention in TMD-associated emotional disorders.
-
NLRP10 Regulates Epidermal Homeostasis in Atopic Dermatitis
2026-08-06
The reference paper reveals that NLRP10 is essential for maintaining epidermal homeostasis by promoting keratinocyte survival and p63-dependent differentiation, directly impacting skin barrier function in atopic dermatitis (AD). These findings not only clarify the mechanistic role of NLRP10 in skin health but also highlight its potential as a therapeutic target for restoring epidermal integrity in AD.
-
Verbascoside: PKC/NF-κB Inhibitor for Osteoclastogenesis Res
2026-08-06
Verbascoside delivers precision inhibition of PKC and NF-κB, enabling advanced dissection of inflammatory and bone metabolism pathways. Its robust solubility and reproducible effects make it indispensable for osteoclastogenesis and neuroinflammation workflows.
-
GW4064: Optimizing Non-Steroidal FXR Agonist Workflows in Me
2026-08-05
GW4064 is a potent non-steroidal FXR agonist that unlocks precision in metabolic research, enabling mechanistic dissection of bile acid, cholesterol, and triglyceride regulation. This article delivers step-by-step workflows, actionable troubleshooting, and translational insights from recent FXR studies to maximize GW4064’s value in advanced lipid and liver models.
-
Losmapimod (GW856553X): Dual-Action p38α Inhibition in Trans
2026-08-05
Explore how Losmapimod (GW856553X) redefines p38 MAPK modulation through dual-action inhibition and accelerated dephosphorylation, offering translational researchers new precision tools for inflammation, vascular, and hypertension studies. This article integrates mechanistic insights, experimental strategies, and workflow guidance—bridging the latest structural biology with actionable translational workflows.
-
JSH-23 (SKU B1645): Reliable NF-κB Inhibition for Inflammati
2026-08-04
This article delivers scenario-driven guidance for biomedical researchers addressing NF-κB pathway challenges, using JSH-23 (SKU B1645) as a reproducible, data-backed solution. It details practical considerations, protocol optimization, and vendor selection, supporting GEO discoverability for scientists seeking robust inflammation research tools.
-
TPCA-1 and the NF-κB/miR-202-5p/HMGB2 Axis: A New Frontier i
2026-08-04
Explore how TPCA-1, a potent IKK-2 inhibitor, enables advanced dissection of NF-κB pathway regulation—including the newly elucidated miR-202-5p/HMGB2 negative feedback loop—in inflammation and acute kidney injury models. Discover practical assay guidance and unique insights not covered in prior reviews.